NASDAQ:CRME TSX:COM
Plenary Symposium Features Three Experts
Discussing Clinical Use
VANCOUVER, Dec. 11, 2017
/CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a
revenue-generating, specialty pharmaceutical company focused on
commercializing patent-protected hospital drugs, today announced a
plenary sponsored symposium at the 2017 National Outpatient
Parenteral Antimicrobial Therapy (OPAT) Conference, hosted by the
British Society for Antimicrobial Chemotherapy, taking place
December 11-12, 2017 in Birmingham, UK.
The Company-sponsored plenary symposium, titled, "Managing
serious skin infections within the changing NHS, time for a
rethink?" will feature presentations by three physician experts
describing treatment and patient experience with Cardiome's
Xydalba™ (dalbavancin hydrochloride), the first and only 30-minute,
one-dose treatment option for acute bacterial skin and skin
structure infections. Cardiome currently markets Xydalba in
France, Germany, the UK, the Republic of Ireland, Belgium, Finland and Sweden.
Details for the symposium are as follows:
- Title: The OPAT patient experience: is there room for
improvement?
Speaker: Dr. Graeme Jones, Consultant in Infection,
Director Infection Prevention Unit, University Hospitals
Southampton
Date and time: December 11, 2017 at 14:15
GMT
- Title: Which patients are unsuitable for OPAT, and how can
they be managed?
Speaker: Dr. John Cunniffe, Consultant Microbiologist
& OPAT Clinical Lead, Wirral University Teaching
Hospital
Date and time: December 11, 2017 at 14:30
GMT
- Title: Dalbavancin in NHSG in the OPAT
setting
Speaker: Sharon
Falconer, Senior OPAT Nurse Specialist, Aberdeen Royal
Infirmary
Date and time: December 11, 2017 at 14:45
GMT
In addition to this Cardiome-sponsored symposium, dalbavancin,
which is marketed in the U.S. as Dalvance® by Allergan) will be
showcased in several additional presentations at the meeting by
physicians describing their clinical experience with the
product.
For more information about BSAC OPAT 2017, please visit
http://opat-conference.com.
About XYDALBA™
Xydalba™ for infusion is a second generation, semi-synthetic
lipoglycopeptide, which consists of a lipophilic side-chain added
to an enhanced glycopeptide backbone. Xydalba is the first and only
30-minute, one-dose treatment option for acute bacterial skin and
skin structure infections (ABSSSI) that delivers a full course of
IV therapy. Xydalba can be administered as either one 1500 mg dose
or as a two-dose regimen of 1000 mg followed one week later by 500
mg, each administered over 30 minutes. Xydalba demonstrates
bactericidal activity in vitro against a range of
Gram-positive bacteria, such as Staphylococcus aureus
(including methicillin-resistant, also known as MRSA, strains) and
Streptococcus pyogenes, as well as certain other
streptococcal species.
About ABSSSI
There were more than 4.8 million hospital admissions of adults
with ABSSSI from 2005 through 2011, which included patients with
cellulitis, erysipelas, wound infection, and major cutaneous
abscess. In fact, hospital admissions for ABSSSI significantly
increased by 17.3 percent during this timeframe. The majority of
all skin and soft tissue infections in hospitalized patients are
caused by streptococci and Staphylococcus aureus, and
approximately 59 percent of these S. aureus infections in
the U.S. are estimated to be caused by MRSA. Early and effective
treatment of ABSSSI is critical to optimize patient recovery and
for certain patients may also help to avoid potentially lengthy and
costly hospital stays.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a revenue-generating, specialty
pharmaceutical company focused on providing innovative,
high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution
network covering over 60 countries worldwide, Cardiome develops,
acquires and commercializes brands for the in-hospital, acute care
market segment. The Company's portfolio of approved and
marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for
the treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a
cephalosporin antibiotic for the treatment of community- and
hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV)
for the rapid conversion of recent onset atrial fibrillation to
sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the
reduction of thrombotic cardiovascular events in patients with
acute coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol
hydrochloride), a short-acting beta-blocker used to control rapid
heart rate in a number of cardiovascular indications. Cardiome's
pipeline of product candidates includes Trevyent®, a drug device
combination that is designed to deliver Treprostinil, the world's
leading treatment for pulmonary arterial hypertension.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the
Toronto Stock Exchange (COM). For more information, please visit
our web site at www.cardiome.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions. Forward-
looking statements may involve, but are not limited to, comments
with respect to our objectives and priorities for 2017 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our
operations, research and development and product and drug
development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward-looking statements. Many such known risks,
uncertainties and other factors are taken into account as part of
our assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business
conditions in the United States,
Canada, Europe, and the other regions in which we
operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with,
governmental legislation and regulations; availability of financial
reimbursement coverage from governmental and third-party payers for
products and related treatments; adverse results or unexpected
delays in pre-clinical and clinical product development processes;
adverse findings related to the safety and/or efficacy of our
products or products; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to expand
commercialization activities; and any other factors that may affect
our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by
the forward-looking statements in this presentation to differ
materially from our actual results. These operating risks include:
our ability to attract and retain qualified personnel; our ability
to successfully complete pre-clinical and clinical development of
our products; changes in our business strategy or development
plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; and the availability of capital to
finance our activities. These and other risks are described in the
Form 40F and associated documents filed March 29, 2017 (see for example, "Risk Factors"
in the Annual Information Form for the year ended December 31, 2016), in the Form 6-K filed
November 14, 2017, and in our other
filings with the Securities and Exchange Commission ("SEC")
available at www.sec.gov and the Canadian securities
regulatory authorities at www.sedar.com. Given these risks,
uncertainties and factors, you are cautioned not to place undue
reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
Cardiome® and the Cardiome Logo are the proprietary
trademarks of Cardiome Pharma Corp.
Aggrastat® and Brinavess® are trademarks
owned by Cardiome and its affiliates worldwide.
Xydalba® is a trademark of Durata Therapeutics Holding
C.V., and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed and used under
license.
All other trademarks are the property of their respective
owners.
SOURCE Cardiome Pharma Corp.